Exatecan

CAT: 0804-HY-13631-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-13631-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Exatecan (DX-8951) is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL), and can be used in cancer research.
CAS Number
[171335-80-1]
Product Name Alternative
DX-8951
UNSPSC
12352005
Hazard Statement
H300, H340, H360
Target
ADC Payload; Topoisomerase
Type
Reference compound
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/exatecan.html
Purity
99.93
Solubility
DMSO : 20 mg/mL (ultrasonic)
Smiles
O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C5C6=C(CC[C@@H]5N)C(C)=C(F)C=C6N=C4C3=C2)=O
Molecular Formula
C24H22FN3O4
Molecular Weight
435.45
Precautions
H300, H340, H360
References & Citations
[1]Mitsui I, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res. 1995 Aug;86 (8) :776-82.|[2]Sun FX, et al. Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res. 2003 Jan 1;63 (1) :80-5.|[3]Joto N, et al. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. Int J Cancer. 1997 Aug 7;72 (4) :680-6.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
Camptothecins
Citation 01
Cornell University. 2025.|Acta Pharmacol Sin. 2025 Sep 10.|Cancer Res. 2025 Oct 9.|Mol Cancer Ther. 2023 Sep 5;22 (9) :1013-1027.|Patent. US20240191272A1.|Research Square Preprint. 2024 Nov 06.|bioRxiv. 2025 April 25.|J Pharm Biomed Anal. 2025 Jun 15:258:116746.|Mol Cancer. 2025 Oct 13;24 (1) :253.|Mol Pharm. 2023 Jan 2;20 (1) :491-499.|Nature. 2024 Apr;628 (8007) :416-423.|New J Chem. 2025 Jan 06.|Patent. US20210009719A1.|Patent. US20220162323A1.|Patent. US20240190973A1.|Patent. US20240216525A1.|Patent. US20240374749A1.|Patent. US20250161295A1.|Patent. US20250161473A1.|Patent. US20250242044A1.|Patent. US20250295798A1.|Pharmaceuticals (Basel) . 2021 Mar 9;14 (3) :247.

Related Products

CatalogName

Popular Products